Main research areas

Expertises

Inflammatory bowel disease; disease course; prognosis; epidemiology; eHealth; clinical research; trials; systematic reviews

Potential conflicts of interest

Dr. Burisch reports grants from AbbVie, Janssen-Cilag, MSD, Takeda, Tillots Pharma, Bristol Myers Squibb, and Novo Nordisk Foundation; personal fees from AbbVie, Janssen-Cilag, Celgene, MSD, Pfizer, Takeda, Tillots Pharma, Bristol Myers Squibb, Samsung Bioepis, Pharmacosmos, Ferring, Galapagos, Eli Lilly, Dr Falk Pharma, and Orion Pharma.

Curriculum

Education

2004 – 2010 Doctor of Medicine (MD), University of Copenhagen, Denmark

2010 – 2013 Doctor of Philosophy (PhD), University of Copenhagen, Denmark

2022 Doctor of Medical Sciences (DMSci, dr.med.), Faculty of Health and Medical Sciences - University of Copenhagen, Denmark

2023 Certified specialist in gastroenterology and hepatology by Danish Health Authority 

Awards & Recognitions

UEG National Scholar Award (Best from Denmark) (2012, 2017); ECCO Presidential Price for young investigators 2013; The Lundbeck Foundation’s Talent Price 2014; Jakobinerklubbens hædersmedajle 2014; ECCO Letter of recognition as conspicuous contributor 2014; Young Investigator Award DDW 2015; ECCO Mark of Merit 2016; UEG Week 2016 poster of excellence; UEG Rising star award 2019; ECCO Young Researcher Award – Clinical/translational science 2023; Erhoff Fondens Talentpris 2024; 

Academic supervision & reviewer activities:

• Currently supervising medical students (5) and PhD-students (7).
• Regular reviewer for the highest-ranking international journals within the field of gastroenterology (including Lancet, Lancet Gastroenterology & Hepatology, Gastroenteorlogy, Gut, American Journal of Gastroenterology, Clinical Gastroenterology & Hepatology).
• Editorial board member for Gut, Alimentary Pharmaceuticals and Therapeutics. Associate editor of the Journal of Crohn’s and Colitis.
• Reviewer for DDW, UEG Week, ECCO Congress

Research grants:

Selected grants include AbbVie (1.200.000 €), Takeda Pharma (400.000 €), Novo Nordisk foundation (161.000 €), Kirsten & Freddy Johansens Founndation (89.000 €), Aage & Louis Hansen Foundation (35.000€), Tillots Pharma (255.000€), MSD (€148.000), Novo Nordisk foundation emerging clinical investigator program (1.300.000 €), MiGut HORIZON-HLTH-2022-STAYHLTH-02 (7,000,000€), Novo Nordisk Foundation Challenge grant 2022 (8,000,000€)

Research leadership:

• Danish Inflammatory bowel disease Biobank (DIB): Principal investigator & founder
• EPI-IBD (formerly EpiCom): occurrence, course and prognosis of inflammatory bowel disease in Europe: Principal investigator & Project manager
• The INCEPTION study - INvestigating the role of genetiCs, immunity, and Environmental factors in the develoPmenT of inflammatory bowel disease ON the Faroe Islands: Principal investigator & founder
• I-CARE – IBD, cancer and serious infections in Europe. A multicentre cohort study regarding the long-term safety profile of immunomodulating therapies in IBD: Scientific committee member & National Coordinator, Denmark
• Implementation of eHealth for self-monitoring of IBD and IBS patients in the Capital Region, Denmark: Principal investigator Development, validation and integration into clinical care of the Constant Care app for self-monitoring of IBD patients
• IBD-Prognosis - The influence of genetics, immunity, and the microbiome on the prognosis of inflammatory bowel disease: Principal investigator

• The CROCO Study: CROhn’s Disease COhort Study, steering group member, co-PI
• Center for intestinal immune regulation (CIIR), Novo Nordisk Challenge Program center of excellence, steering group member

Dissemination:

Author of >220 papers on PubMed & 3 book chapters; H-index (Google scholar): 60

Invited lectures on IBD epidemiology and disease course: >50. Oral presentations of original research at UEG Week, DDW, ECCO Congress: >50.

Board positions & committees:

• European Crohn’s & Colitis Organization: Epidemiological Committee (2010-2014), Young-ECCO (2017-2021, Chair 2020-2021), Guideline Committee 2024-2027
• United European Gastroenterology: Young Talent Group (2013-2018, chair 2016-2017), Scientific Committee (2013-2015), National Societies Committee (2016-2017)
• Danish Society of Gastroenterology and Hepatology: Young Trainee section (2012-2017), Research committee (2016-currently), BIOIBD registry, committee member (2019 – currently)
• International Organization For the Study of Inflammatory Bowel Disease (IOIBD) since 2023

Working groups:

• Consensus rapports for European Crohn’s & Colitis Organization: Extra-Intestinal Manifestations in IBD, Ulcerative Colitis, Crohn’s disease, Diagnostic Techniques & Monitoring, Malignancies in IBD
• European Crohn’s & Colitis Organization Topical reviews: Environmental Factors, Exit Strategies for IBD Treatments, Refractory IBD.
• Danish Guideline for: fistulizing Crohn’s disease, acute severe colitis & mild-moderate ulcerative colitis
• The Lancet Gastroenterology & Hepatology: The Costs of Inflammatory Bowel Diseases in High-Income Settings – Commission leader